e application of these technologies in the
development of a full range of microRNA-based diagnostic and therapeutic
tools, focusing primarily on cancer and various women's health indications.
The first microRNA diagnostic test applying Rosetta Genomics' technology
has been approved for clinical use by the State of New York, and the
company expects it will be launched by licensed clinical laboratories in
the United States in 2008.